Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports.

Infection - 1 Feb 2005

Scotto G, Palumbo E, Fazio V, Cibelli D C, Saracino A, Angarano G

Abstract excerpt

Acute hepatitis C often progresses to chronic infection (70%). In this clinical study, we evaluated if early treatment with peginterferon alfa-2b can prevent acute hepatitis C from developing into a chronic disease. Six patients with acute hepatitis C, based on a well-documented hepatitis C virus (HCV) seroconversion with high alanine aminotransferase (ALT) levels (> 10 x ULN) and persistent HCV RNA titers after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Antiviral Agents
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Viral Load

Source

Identifiers

PMID: 15750757
DOI: 10.1007/s15010-005-4032-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports.PMID 15750757Read ↗

Response and seroconversion rates among HBeAg-positive chronic HBV Egyptian patients treated with peginterferon alpha 2a (Pegasys), a single-centre experience.Semantic proximity Read ↗

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.Semantic proximity Read ↗

DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.Semantic proximity Read ↗

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.Semantic proximity Read ↗

Pegylated interferon alpha-2b in patients with acute hepatitis C.Semantic proximity Read ↗

Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study.Semantic proximity Read ↗

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.Semantic proximity Read ↗

High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.Semantic proximity Read ↗

Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.Semantic proximity Read ↗

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.Semantic proximity Read ↗

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.Semantic proximity Read ↗

Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.